- Home
- DNTH vs RLAY Comparison
DNTH vs RLAY Comparison
Compare DNTH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- RLAY
- Stock Information
- Founded
- DNTH 2015
- RLAY 2015
- Country
- DNTH United States
- RLAY United States
- Employees
- DNTH N/A
- RLAY N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNTH Health Care
- RLAY Health Care
- Exchange
- DNTH Nasdaq
- RLAY Nasdaq
- Market Cap
- DNTH 724.8M
- RLAY 620.4M
- IPO Year
- DNTH N/A
- RLAY 2020
- Fundamental
- Price
- DNTH $18.14
- RLAY $2.62
- Analyst Decision
- DNTH Strong Buy
- RLAY Strong Buy
- Analyst Count
- DNTH 8
- RLAY 10
- Target Price
- DNTH $54.33
- RLAY $19.33
- AVG Volume (30 Days)
- DNTH 362.0K
- RLAY 2.5M
- Earning Date
- DNTH 03-11-2025
- RLAY 05-01-2025
- Dividend Yield
- DNTH N/A
- RLAY N/A
- EPS Growth
- DNTH N/A
- RLAY N/A
- EPS
- DNTH N/A
- RLAY N/A
- Revenue
- DNTH $6,235,000.00
- RLAY $10,007,000.00
- Revenue This Year
- DNTH N/A
- RLAY N/A
- Revenue Next Year
- DNTH N/A
- RLAY $544.28
- P/E Ratio
- DNTH N/A
- RLAY N/A
- Revenue Growth
- DNTH 120.63
- RLAY N/A
- 52 Week Low
- DNTH $17.50
- RLAY $2.45
- 52 Week High
- DNTH $32.27
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- DNTH 36.91
- RLAY 32.07
- Support Level
- DNTH $17.50
- RLAY $3.05
- Resistance Level
- DNTH $20.45
- RLAY $3.08
- Average True Range (ATR)
- DNTH 1.67
- RLAY 0.25
- MACD
- DNTH -0.22
- RLAY -0.04
- Stochastic Oscillator
- DNTH 10.44
- RLAY 11.64
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).